Literature DB >> 36278991

Recent advances in cutaneous lymphoma-implications for current and future classifications.

J R Goodlad1, L Cerroni2, S H Swerdlow3.   

Abstract

The Revised European-American Classification of mature lymphoid neoplasms published in 1994 and the 2001, 2008 and 2016 WHO classifications that followed, were the product of international collaboration and consensus amongst haematopathologists, geneticists, molecular scientists and clinicians. Primary cutaneous lymphomas were fully incorporated into this process following the publication of the WHO-EORTC classification of cutaneous lymphomas in 2005. The definition, diagnostic criteria and recommended studies for primary cutaneous lymphoma continue to be refined. The 2022 International Consensus Classification represents the most recent update and an overview of all the main entities presenting primarily in the skin, together with the major changes in classification, are summarized herein. Primary cutaneous marginal zone lymphoma is segregated from other extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma) and downgraded to a lymphoproliferative disorder in line with its markedly indolent behaviour. In addition, two subtypes are recognised, based largely but not exclusively on whether they are heavy chain class-switched or IgM positive. Similarly, in keeping with a trend to greater conservatism, primary cutaneous acral CD8 positive T cell lymphoma is now also classified as a lymphoproliferative disorder. In addition, significant new insights into the biology of primary cutaneous lymphoma have also recently been forthcoming and will be presented. These studies have enhanced our knowledge of genetic, epigenetic and transcriptional changes in this group of diseases. They not only identify potential targets for novel therapies, but also raise as yet unanswered questions as to how we categorise cutaneous lymphomas, particularly with respect to relationships with similar lymphomas at extracutaneous sites.
© 2022. Crown.

Entities:  

Keywords:  Classification; Cutaneous; Lymphoma; Lymphoproliferative disorder

Year:  2022        PMID: 36278991     DOI: 10.1007/s00428-022-03421-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  78 in total

Review 1.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.

Authors:  R Willemze; H Kerl; W Sterry; E Berti; L Cerroni; S Chimenti; J L Diaz-Peréz; M L Geerts; M Goos; R Knobler; E Ralfkiaer; M Santucci; N Smith; J Wechsler; W A van Vloten; C J Meijer
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

2.  Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases.

Authors:  Eric D Carlsen; Steven H Swerdlow; James R Cook; Sarah E Gibson
Journal:  Am J Surg Pathol       Date:  2019-10       Impact factor: 6.394

Review 3.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

4.  Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.

Authors:  Octavio Servitje; Cristina Muniesa; Yolanda Benavente; Verónica Monsálvez; M Pilar Garcia-Muret; Fernando Gallardo; Eva Domingo-Domenech; Anna Lucas; Fina Climent; Jose L Rodriguez-Peralto; Pablo L Ortiz-Romero; Juan Sandoval; Ramon M Pujol; M Teresa Estrach
Journal:  J Am Acad Dermatol       Date:  2013-06-21       Impact factor: 11.527

Review 5.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

6.  Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.

Authors:  Laurence de Leval; Ash A Alizadeh; P Leif Bergsagel; Elias Campo; Andrew John Davies; Ahmet Dogan; Jude Fitzgibbon; Steven M Horwitz; Ari M Melnick; William George Morice; Ryan D Morin; Bertrand Nadel; Stefano A Pileri; Richard Rosenquist; Davide Rossi; Itziar Salaverria; Christian Steidl; Steven P Treon; Andrew D Zelenetz; Ranjana Advani; Carl E Allen; Stephen M Ansell; Wing C Chan; James R Cook; Lucy B Cook; Francesco d'Amore; Stefan Dirnhofer; Martin Dreyling; Kieron Dunleavy; Andrew Feldman; Falko Fend; Philippe Gaulard; Paolo Ghia; John G Gribben; Olivier Hermine; Daniel J Hodson; Eric D Hsi; Giorgio Ga Inghirami; Elaine S Jaffe; Kennosuke Karube; Keisuke Kataoka; Wolfram Klapper; Won Seog Kim; Rebecca L King; Young Hyeh Ko; Ann S LaCasce; Georg Lenz; Iñaki Martin-Subero; Miguel A Piris; Stefania Pittaluga; Laura Pasqualucci; Leticia Quintanilla-Martinez; Scott J Rodig; Andreas Rosenwald; Gilles A Salles; Jesus San-Miguel; Kerry J Savage; Laurie H Sehn; Gianpietro Semenzato; Louis M Staudt; Steven Howard Swerdlow; Constantine S Tam; Judith Trotman; Julie Vose; Oliver Weigert; Wyndham H Wilson; Jane N Winter; Catherine J Wu; Pier Luigi Zinzani; Emanuele Zucca; Adam Bagg; David W W Scott
Journal:  Blood       Date:  2022-08-24       Impact factor: 25.476

7.  Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.

Authors:  Eric J Duncavage; Adam Bagg; Robert P Hasserjian; Courtney D DiNardo; Lucy A Godley; Ilaria Iacobucci; Siddhartha Jaiswal; Luca Malcovati; Alessandro M Vannucchi; Keyur P Patel; Daniel A Arber; Maria E Arcila; Rafael Bejar; Nancy Berliner; Michael J Borowitz; Susan Branford; Anna L Brown; Catherine A Cargo; Hartmut Döhner; Brunangelo Falini; Guillermo Garcia-Manero; Torsten Haferlach; Eva Hellström-Lindberg; Annette S Kim; Jeffery M Klco; Rami S Komrokji; Mignon L Loh; Sanam Loghavi; Charles G Mullighan; Seishi Ogawa; Ayalew Tefferi; Elli Papaemmanuil; Andreas Reiter; David Morrall Ross; Michael R Savona; Akiko Shimamura; Radek C Skoda; Francesc Sole; Richard M Stone; Attilio Orazi; Matthew J Walter; David Wu; Benjamin L Ebert; Mario Cazzola
Journal:  Blood       Date:  2022-09-21       Impact factor: 25.476

8.  Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression.

Authors:  Isabel Brenner; Sabine Roth; Bernhard Puppe; Marion Wobser; Andreas Rosenwald; Eva Geissinger
Journal:  Mod Pathol       Date:  2013-06-14       Impact factor: 7.842

9.  How I Diagnose Primary Cutaneous Marginal Zone Lymphoma.

Authors:  Sarah E Gibson; Steven H Swerdlow
Journal:  Am J Clin Pathol       Date:  2020-09-08       Impact factor: 2.493

10.  IRTA1 positivity helps identify a MALT-lymphoma-like subset of primary cutaneous marginal zone lymphomas, largely but not exclusively defined by IgM expression.

Authors:  Eric D Carlsen; Shweta Bhavsar; James R Cook; Steven H Swerdlow
Journal:  J Cutan Pathol       Date:  2021-08-08       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.